Adherence Support Approaches in Biomedical HIV Prevention Trials: Experiences, Insights and Future Directions from Four Multisite Prevention Trials

Amico, K.; Mansoor, Leila; Corneli, Amy; Torjesen, Kristine; Straten, Ariane
July 2013
AIDS & Behavior;Jul2013, Vol. 17 Issue 6, p2143
Academic Journal
Adherence is a critical component of the success of antiretroviral-based pre-exposure prophylaxis (PrEP) in averting new HIV-infections. Ensuring drug availability at the time of potential HIV exposure relies on self-directed product use. A deeper understanding of how to best support sustained PrEP adherence remains critical to current and future PrEP efforts. This paper provides a succinct synthesis of the adherence support experiences from four pivotal PrEP trials-Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004, FEM-PrEP, Iniciativa Prophylaxis (iPrEx), and Vaginal and Oral Interventions to Control the Epidemic (VOICE). Notwithstanding variability in the design, population/cohort, formulation, drug, dosing strategy, and operationalization of adherence approaches utilized in each trial, the theoretical basis and experiences in implementation and monitoring of the approaches used by these trials provide key lessons for optimizing adherence in future research and programmatic scale-up of PrEP. Recommendations from across these trials include participant-centered approaches, separating measurement of adherence from adherence counseling, incorporating tailored strategies that go beyond education, fostering motivation, and addressing the specific context in which an individual incorporates and negotiates PrEP use.


Related Articles

  • Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case-Control Study. MacQueen, Kathleen; Weaver, Mark; Loggerenberg, Francois; Succop, Stacey; Majola, Nelisle; Taylor, Doug; Karim, Quarraisha; Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p826 

    Adherence undeniably impacts product effectiveness in microbicide trials, but the connection has proven challenging to quantify using routinely collected behavioral data. We explored this relationship using a nested case-control study in the CAPRISA 004 Tenofovir (TFV) gel HIV prevention trial....

  • Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial. Mansoor, Leila; Abdool Karim, Quarraisha; Yende-Zuma, Nonhlanhla; MacQueen, Kathleen; Baxter, Cheryl; Madlala, Bernadette; Grobler, Anneke; Abdool Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p811 

    High adherence is key to microbicide effectiveness. Here we provide a description of adherence interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir gel trial. Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly...

  • Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting. Baisley, Kathy; Baeten, Jared; Hughes, James; Donnell, Deborah; Wang, Jing; Hayes, Richard; Jones, Deborah; Celum, Connie // AIDS & Behavior;Nov2013, Vol. 17 Issue 9, p3108 

    For trials of user-dependent HIV prevention products, accurate adherence measurements are essential to interpret and compare results across trials. We used pill count data from two recent HIV prevention trials of herpes simplex virus type 2 (HSV-2) suppression, to show that estimates of...

  • Masivukeni: Development of a Multimedia Based Antiretroviral Therapy Adherence Intervention for Counselors and Patients in South Africa. Remien, Robert; Mellins, Claude; Robbins, Reuben; Kelsey, Ryan; Rowe, Jessica; Warne, Patricia; Chowdhury, Jenifar; Lalkhen, Nuruneesa; Hoppe, Lara; Abrams, Elaine; El-Bassel, Nabila; Witte, Susan; Stein, Dan // AIDS & Behavior;Jul2013, Vol. 17 Issue 6, p1979 

    Effective medical treatment for HIV/AIDS requires patients' optimal adherence to antiretroviral therapy (ART). In resource-constrained settings, lack of adequate standardized counseling for patients on ART remains a significant barrier to adherence. Masivukeni ('Let's Wake Up' in Xhosa) is an...

  • HIV pre-exposure prophylaxis. F. Morin, Stephen; Yamey, Gavin; W. Rutherford, George // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/25/2012, Vol. 345 Issue 7871, p10 

    The article reports that the FDA has approved a fixed dose combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC; Truvada) as a once daily pill for prevention of Human immunodeficiency virus (HIV) infection in at risk adults. Studies have shown prophylactic treatment to be...

  • Impact of an Adherence Intervention on the Effectiveness of Tenofovir Gel in the CAPRISA 004 Trial. Mansoor, Leila; Karim, Quarraisha; Werner, Lise; Madlala, Bernadette; Ngcobo, Nelisiwe; Cornman, Deborah; Amico, K.; Fisher, Jeffrey; Fisher, William; MacQueen, Kathleen; Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p841 

    High adherence is important in microbicide trials, but no adherence interventions to date have demonstrated empiric improvements in microbicide adherence or effectiveness. Approximately midway during the CAPRISA 004 trial, we implemented a novel adherence intervention (Adherence Support...

  • Monitoring Microbicide Gel Use with Real-Time Notification of the Container's Opening Events: Results of the CAPRISA Wisebag Study. Gengiah, Tanuja; Upfold, Michele; Naidoo, Anushka; Mansoor, Leila; Feldblum, Paul; Abdool Karim, Quarraisha; Abdool Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p833 

    Accurate estimation of the effectiveness of a microbicide for HIV prevention requires valid measurement of adherence to product use. A microbicide gel applicator container (Wisebag), fitted with cell phone technology to transmit opening events and text message reminders, was developed to monitor...

  • Effects of Partnership Change on Microbicide Gel Adherence in a Clinical Trial (HPTN 035). Gorbach, Pamina; Kelly, Clifton; Borgerding, Joleen; Ramjee, Gita; Tembo, Tchangani; Kumwenda, Newton; Musara, Petina; Roberts, Sarah; Maslankowski, Lisa // AIDS & Behavior;May2014, Vol. 18 Issue 5, p855 

    Use of HIV prevention methods may vary for women by types of sexual partners. In a microbicide safety and effectiveness trial (HPTN 035) differences in adherence to a microbicide study gel were compared between women with new versus ongoing partnerships over time. 1,757 women in the three HPTN...

  • Measuring Adherence by Visual Inspection of Returned Empty Gel Applicators in the CAPRISA 004 Microbicide Trial. Gengiah, Tanuja; Mansoor, Leila; Upfold, Michele; Naidoo, Anushka; Yende-Zuma, Nonhlanhla; Kashuba, Angela; Karim, Quarraisha; Karim, Salim // AIDS & Behavior;May2014, Vol. 18 Issue 5, p820 

    In the CAPRISA 004 trial, adherence was estimated as the proportion of reported sex acts covered by two gel doses, which was assessed by counting returned empty gel applicators. The returned empty applicators were inspected visually in a standardized manner for residue on the outside of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics